Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Voyager Therapeutics ( (VYGR) ) has issued an update.
Voyager Therapeutics has posted a new corporate investor presentation on its website and circulated a summary letter to select shareholders, outlining a 2026 investment case built around validating brain-targeted capsids in humans, a “transformative” year for its tau-focused Alzheimer’s programs, and demonstrating the value of its Voyager NeuroShuttle platform. The materials highlight a multi-modality CNS pipeline with two key Alzheimer’s candidates—VY7523, an anti-tau antibody, and VY1706, a tau-silencing gene therapy—alongside partnered gene therapies for Friedreich’s ataxia, Gaucher’s and Parkinson’s disease and a small-molecule program for ALS/FTD, and detail plans to complete GLP toxicology, file an IND, and begin first-in-human dosing of VY1706 in the second half of 2026 after encouraging non-human primate data on tau knockdown and liver de-targeting. The company emphasizes the potential for third-party clinical readouts, notably Biogen’s BIIB080 Phase 2 data expected mid-2026, to validate the tau knockdown approach, and underscores that its forward-looking development timelines, partnership economics and cash sufficiency remain subject to scientific, regulatory, competitive and collaboration risks disclosed in its SEC filings.
The most recent analyst rating on (VYGR) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Voyager Therapeutics stock, see the VYGR Stock Forecast page.
Spark’s Take on VYGR Stock
According to Spark, TipRanks’ AI Analyst, VYGR is a Neutral.
The overall stock score of 46 reflects significant financial performance challenges, including declining revenues and profitability issues. Technical analysis indicates bearish momentum, and the negative P/E ratio highlights valuation concerns. The absence of earnings call data and corporate events limits additional insights.
To see Spark’s full report on VYGR stock, click here.
More about Voyager Therapeutics
Voyager Therapeutics (NASDAQ: VYGR) is a biotechnology company focused on neurogenetic medicines for central nervous system disorders, leveraging gene therapy, antibodies, its TRACER capsid discovery platform, and emerging non-viral and small-molecule approaches. Its pipeline targets Alzheimer’s disease, Friedreich’s ataxia, Gaucher’s disease, Parkinson’s disease, ALS and frontotemporal dementia, with programs advanced through a mix of wholly owned assets and collaborations with partners including Neurocrine, Novartis, Alexion and Transition Bio, and management indicating a cash runway into 2028 based on current plans and collaboration reimbursements.
Average Trading Volume: 494,532
Technical Sentiment Signal: Sell
Current Market Cap: $223.5M
Learn more about VYGR stock on TipRanks’ Stock Analysis page.